Sibylle Loibl: Outcomes of Targeted Axillary Surgery
Sibylle Loibl, Chief Executive Officer of GBG Forschungs GmbH, shared a post on LinkedIn:
“New Publication in EJSO: Lost Axillary Markers After Neoadjuvant Chemotherapy – Insights from the AXSANA (EUBREAST 3) Study
The prospective AXSANA cohort study (EUBREAST 3) investigated outcomes of targeted axillary surgery – specifically target lymph node biopsy and targeted axillary dissection in breast cancer patients after neoadjuvant chemotherapy (NACT), focusing on the impact of lost axillary markers.
Key findings:
- In 5.8% (88 of 1528) of patients, marked lymph nodes could not be retrieved during surgery following NACT.
- The loss rate varied significantly by marker type: Metal clips/coils: 7.0%; Carbon: 3.1%; Radar reflector: 1.4%; Magnetic seed: 0.6%; Radioactive seed: 0.0%
- Additional imaging was required in 28.4% of cases with lost markers; 6.8% underwent further surgery.
- There was no significant difference in the rates of axillary lymph node dissection or radiotherapy between patients with or without lost markers.
- A non-significant trend toward higher axillary recurrence was observed in patients with lost markers (3.3% vs. 1.0%; rate ratio 2.89, p = 0.088).
Conclusion:
Loss of axillary markers after NACT is uncommon, but highly dependent on the marking technique. While clinical consequences like additional procedures and imaging can occur, oncologic outcomes appear largely unaffected. These findings underscore the importance of marker selection and placement in targeted axillary surgery.”
Title: Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients – data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655)
Authors: Steffi Hartmann, Maggie Banys-Paluchowski, Tomasz Berger, Nina Ditsch, Elmar Stickeler, Jana de Boniface, Oreste Davide Gentilini, Jennifer Schroth, Guldeniz Karadeniz Cakmak, Isabel T. Rubio, Maria Luisa Gasparri, Michalis Kontos, Eduard-Alexandru Bonci, Laura Niinikoski, Dawid Murawa, Geeta Kadayaprath, David Pinto, Florentia Peintinger, Ellen Schlichting, Lukas Dostalek, Helidon Nina, Hagigat Valiyeva, Marian Vanhoeij, Andraž Perhavec, Douglas Zippel, Lia Pamela Rebaza, Sarun Thongvitokomarn, Sarah Fröhlich, Franziska Ruf, Angelika Rief, Kristina Wihlfahrt, Timo Basal, Marc Thill, Michael Patrick Lux, Sibylle Loibl, Hans-Christian Kolberg, Jens-Uwe Blohmer, Markus Hahn, Meryem Gunay Gurleyik, Mauro Porpiglia, Semra Gunay, Linda Zetterlund, Thorsten Kuehn
Read the Full Article.
More posts featuring Sibylle Loibl.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023